Kaneka Eurogentec vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison
How does Kaneka Eurogentec compare to Merck KGaA / MilliporeSigma (CDMO) for mRNA/LNP manufacturing?
Side-by-side comparison of Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) qualify as mRNA/LNP manufacturers; Merck KGaA / MilliporeSigma (CDMO) carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Kaneka Eurogentec vs Merck KGaA / MilliporeSigma (CDMO)
How does Kaneka Eurogentec compare to Merck KGaA / MilliporeSigma (CDMO) for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Kaneka Eurogentec is 82/100 and Merck KGaA / MilliporeSigma (CDMO) is 82/100; Kaneka Eurogentec has 1 FDA inspection on record vs 2 for Merck KGaA / MilliporeSigma (CDMO); European coverage is 4 active EMA+MHRA certificates for Kaneka Eurogentec vs 2 for Merck KGaA / MilliporeSigma (CDMO). Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Kaneka Eurogentec or Merck KGaA / MilliporeSigma (CDMO)?
Both Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Kaneka Eurogentec has 1 FDA inspection on record; Merck KGaA / MilliporeSigma (CDMO) has 2.
How do Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?
Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Kaneka Eurogentec or Merck KGaA / MilliporeSigma (CDMO)?
Kaneka Eurogentec is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — Kaneka Eurogentec or Merck KGaA / MilliporeSigma (CDMO)?
Both Kaneka Eurogentec and Merck KGaA / MilliporeSigma (CDMO) are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →